FDA explains the ins and outs of real-time oncology review program in new guidance
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyResearch, Design and Development